BenzingaT3·4mo ago
VTGN Vistagen Therapeutics, Inc. Common Stock
XNAS
0.17
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VTGN
$0.17
—
Key stats
$0.17
Pre-market
$0.17
-2.19%
- 52-Week Range
- $0.17 – $5.14
- YTD
- -74.40%
- Straddle Price
- $15.00
- P/C Vol Ratio
- 0.04
- Market Cap
- $0.0B
- Open
- $0.18
- Day Range
- $0.17 – $0.18
- Volume
- 765,935
- Prev Close
- $0.18
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 1.16 |
| Cost of Equity (CAPM) | 11.49% (VRP-adj) |
| WACC | 11.45% |
| Volatility Risk Premium | +248.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -276.2% |
| Book / Price | 534.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -4912.0% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $0.25 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.24 |
| Bollinger Width / SMA20 | 28237.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ANRO, NBIX, RLMD
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$1.11
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $3.78 | 24% | median 3.9× · 3 peers |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $0.25 | 76% | stability 60% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 41
- List Date
- 2009-07-01
- CIK
- 0001411685
- Next Earnings
- 2026-11-12 (After-Close)
- EPS Forecast
- ($0.37) (1 est.)
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.vistagen.com
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a var…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -7.42% | -22.01% | 99.08% | -7.18% | -12.82% | -17.79% | 5.31% |
| Feb | 15.42% | -14.11% | -29.16% | 6.46% | -7.22% | 1.12% | -4.58% |
| Mar | -11.62% | -9.49% | -28.99% | 4.14% | 0.40% | -4.16% | -8.29% |
| Apr | 15.53% | 10.43% | 5.98% | -10.56% | 0.00% | 2.13% | 3.92% |
| May | -2.63% | -10.16% | 0.85% | -18.57% | 9.32% | 0.67% | -3.42% |
| Jun | 21.15% | -22.81% | -55.85% | -11.45% | -17.53% | -65.10% | -25.27% |
| Jul | -22.90% | -83.59% | -9.90% | -3.92% | 42.79% | -3.21% | -13.46% |
| Aug | 10.55% | 28.04% | 196.11% | 3.71% | 14.38% | 4.08% | 42.81% |
| Sep | -10.46% | -10.58% | -11.49% | -10.42% | 0.85% | 26.51% | -2.60% |
| Oct | -14.87% | -17.38% | -24.29% | 0.65% | 10.99% | -38.50%* | -13.90% |
| Nov | -19.58% | 3.91% | 17.70% | -8.68% | 15.57% | -- | 1.78% |
| Dec | 9.55% | -24.26% | 40.82% | 4.24% | -85.06% | -- | -10.94% |
| Total | -26.33% | -94.33% | 40.03% | -43.24% | -76.89% | -77.59% | -46.39% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.23
SMA 50: $0.24
SMA 200: $0.46
Current: $0.17
EMA 12: $0.20
EMA 26: $0.23
MACD: -0.0217 | Signal: -0.0058
BEARISH
ADX (14): 19.36
RANGE
+DI: 23.79
−DI: 27.72
Momentum Oscillators
RSI (14): 30.55
NEUTRAL
Stoch %K: 4.37
Stoch %D: 3.12
Williams %R: -93.78
Volume & Volatility
BB Upper: $0.31
BB Lower: $0.15
NEUTRAL
OBV: 544,006,873
Vol SMA 20: 1,125,363
Vol ROC: 3.46%
ATR: $0.02
True Range: $0.01
HV 20: 50.1%
HV 30: 146.5%
HV 60: 116.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: BEARISH (confidence level: 8/10)
Key drivers:
- Technical indicators pointing to a bearish trend
- High volatility, indicating high risk
- Negative news sentiment from recent headlines
Primary risks:
- Regulatory issues or negative developments in the company's pipeline
- Continued market volatility and potential further declines
Investment thesis: VTGN is currently trending downward due to a combination of technical and fundamental factors. The stock's high volatility and beta above 1.5 indicate a high level of risk, making it challenging for investors to predict future price movements.
Recent news sentiment impact: The recent headlines are all negative, focusing on potential investor harm from alleged securities fraud. This has contributed to the bearish trend in VTGN's stock price.
Technical Analysis
Trend direction:
- Short-term: Bearish
- Medium-term: Downtrend
- Long-term: Neutral (stock has been trending downward, but lacks clear direction)
Support/resistance levels:
- Resistance level: $0.32 (SMA 50)
- Support level: $0.22 (Bollinger Band Lower)
Momentum signals:
- RSI interpretation: Neutral (44.72), indicating a lack of momentum
- MACD signal: Bearish (crossover below signal line)
- Bollinger Bands position: Squeeze, suggesting potential volatility and price movement
Volume analysis:
- Volume SMA 20: 7219043.83 (indicating increasing volume)
- On-Balance Volume (OBV): -6814904.44 (suggesting selling pressure)
News & Sentiment Analysis
Recent headlines summary:
- All recent headlines are negative, focusing on potential investor harm from alleged securities fraud.
Sentiment assessment: Aggregate news sentiment is strongly bearish, with a rating of -3/5.
Catalyst identification: No imminent catalysts identified. However, regulatory issues or negative developments in the company's pipeline could further impact the stock price.
Market narrative: The recent headlines have contributed to a bearish trend in VTGN's stock price, which is likely to continue unless there is a significant shift in market sentiment or news flow.
Risk & Volatility Assessment
Risk assessment:
- Beta: 1.67 (high risk)
- Volatility regime: High (stock moves more than the market)
- Options market signals:
- IV rank: 39.1% (medium - shows if volatility is historically high/low)
- Current IV: 520.7% (indicating high implied volatility)
Downside protection: Support levels and risk management considerations:
- Critical price level: $0.22 (Bollinger Band Lower)
- Breakout/breakdown levels: $0.32 (SMA 50) and $0.26 (current price)
Market Context & Positioning
Market performance:
- Relative strength vs sector/market: Weak
Institutional activity: Volume patterns suggesting institutional interest are not evident.
Correlation analysis: VTGN's stock moves more than the market, indicating high volatility.
Relative valuation: Position within trading range:
- Critical price level: $0.26 (current price)
- Support/resistance levels: $0.22 and $0.32
Key Levels & Action Items
Critical price levels:
- Support level: $0.22 (Bollinger Band Lower)
- Resistance level: $0.32 (SMA 50)
Breakout/breakdown levels:
- Critical price level: $0.26 (current price)
- Breakout level: $0.32 (SMA 50) and $0.40 (SMA 200)
Time-sensitive catalysts: No imminent catalysts identified.
Risk management:
- Stop-loss levels: Consider setting stop-loss orders near critical price levels.
- Position sizing considerations: Be cautious when entering new positions, as the stock's high volatility and beta above 1.5 indicate a high level of risk.
Generated
News
All VTGN news →
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·7mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
15 of 16 under expected move
Avg Expected Move
43.02%
Avg Actual Move
5.19%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-02-10 | After-Close | 3.46% | 2.60% | 0.75x | Within |
| 2022-06-23 | After-Close | 1.19% | 5.40% | 4.54x | Exceeded |
| 2022-08-11 | After-Close | 16.19% | 10.06% | 0.62x | Within |
| 2023-06-28 | After-Close | 43.58% | 4.65% | 0.11x | Within |
| 2023-11-09 | After-Close | 16.61% | 11.07% | 0.67x | Within |
| 2024-02-13 | After-Close | 11.84% | 10.00% | 0.84x | Within |
| 2024-06-11 | After-Close | 23.21% | 2.12% | 0.09x | Within |
| 2024-08-13 | After-Close | 19.17% | 3.24% | 0.17x | Within |
| 2024-11-07 | After-Close | 22.44% | 0.64% | 0.03x | Within |
| 2025-02-13 | Pre-Market | 83.94% | 4.01% | 0.05x | Within |
| 2025-06-17 | After-Close | 21.01% | 13.45% | 0.64x | Within |
| 2025-08-07 | Pre-Market | 24.41% | 8.08% | 0.33x | Within |
| 2025-11-13 | After-Close | 23.03% | 0.00% | 0.00x | Within |
| 2026-02-12 | After-Close | 146.79% | 7.23% | 0.05x | Within |
| 2026-06-16 | After-Close | 134.57% | 0.00% | 0.00x | Within |
| 2026-08-14 | Pre-Market | 96.83% | 0.49% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VTGN Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $15.00
7-DTE Move: $15.00
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 180
Put Volume: 7
P/C Volume: 0.039
BULLISH
Call OI: 6,204
Put OI: 1,177
P/C OI: 0.19
Total OI: 7,381
ATM Options Pricing
ATM Call: $7.50
ATM Put: $7.50
Call %: 4315.3%
Put %: 4315.3%
Chain Summary
Chain Volume: 429
Chain OI: 18,291
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 42nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
42%
vs own history
GEX tilt
+0.55
OI-weighted, today
Vanna tilt
+0.57
δ-sensitivity to IV
Charm tilt
-0.61
δ-decay vs time
Vanna tilt +0.57: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.61: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 594.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$15.00Oct 26
Beta Analysis
Risk Metrics
Beta: 1.3183
Alpha: -158.83%
Correlation: 0.1180
R-Squared: 1.4%
Stock Volatility: 142.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own VTGN
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $165K | #2919 of 3138 | +150.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $16K | #6204 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VTGN Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 36,997,039 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
9 filers$333.10K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $95.54K | 28.68% | 2026-06-30 |
| 2 | Millennium Management LLC Custodian | $69.29K | 20.80% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $42.13K | 12.65% | 2026-06-30 |
| 4 | TUDOR INVESTMENT CORP ET AL | $37.74K | 11.33% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $33.67K | 10.11% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $24.00K | 7.21% | 2026-06-30 |
| 7 | Jane Street Group, LLC Custodian | $17.29K | 5.19% | 2026-06-30 |
| 8 | DIADEMA PARTNERS LP | $13.04K | 3.91% | 2026-06-30 |
| 9 | Persistent Asset Partners Ltd | $394 | 0.12% | 2026-06-30 |
5 filers$32.41K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $12.75K | 39.33% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $10.19K | 31.44% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $5.54K | 17.09% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $3.41K | 10.53% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $520 | 1.60% | 2026-06-30 |
VTGN Insider Trading (Form 4)
Latest: 2026-07-31Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Douglas J Williamson | Director | Grant (A) | +40,826 opt | — | EDGAR | |
| 2026-07-02 | Nick B. Tressler | Chief Financial Officer | Award (A) | +11,712 | $0.19 | $2.2K | EDGAR |
| 2026-07-02 | Shawn Singh | President and CEO | Award (A) | +36,818 | $0.19 | $7.1K | EDGAR |
| 2026-07-02 | Reid G. Adler | Chief Legal Officer | Award (A) | +36,818 | $0.19 | $7.1K | EDGAR |
| 2026-05-19 | Angel S Angelov | Chief Medical Officer | Grant (A) | +150,000 opt | — | EDGAR | |
| 2026-04-09 | Elissa S. Cote | Chief Corp Development Officer | Grant (A) | +75,000 opt | — | EDGAR | |
| 2026-04-09 | Nick B. Tressler | Chief Financial Officer | Grant (A) | +75,000 opt | — | EDGAR | |
| 2026-04-09 | Reid G. Adler | Chief Legal Officer | Grant (A) | +75,000 opt | — | EDGAR | |
| 2026-04-09 | Joshua S. Prince | Chief Operating Officer | Grant (A) | +75,000 opt | — | EDGAR | |
| 2026-04-09 | Shawn Singh | President and CEO | Grant (A) | +75,000 opt | — | EDGAR | |
| 2026-01-05 | Joshua S. Prince | Chief Operating Officer | Award (A) | +4,386 | $0.56 | $2.5K | EDGAR |
| 2025-12-04 | Nick B. Tressler | Chief Financial Officer | Grant (A) | +150,000 RSU | — | EDGAR | |
| 2025-11-04 | Paul R Edick | Director | Grant (A) | +35,200 opt | — | EDGAR | |
| 2025-09-11 | Mary L. Rotunno | Director | Grant (A) | +17,600 opt | — | EDGAR | |
| 2025-09-11 | Jon S Saxe | Director | Grant (A) | +17,600 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VTGN Insider Holdings
6 insiders · @ $0.17
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Shawn Singh | President and CEO | 75,721 | $13.2K | $103.2K | 29 | 2026-07-02 |
| 2 | Reid G. Adler | Chief Legal Officer | 60,868 | $10.6K | $50.9K | 10 | 2026-07-02 |
| 3 | Joshua S. Prince | Chief Operating Officer | 15,249 | $2.7K | $0 | 7 | 2026-04-09 |
| 4 | Cynthia Lynn Anderson | CHIEF FINANCIAL OFFICER | 12,801 | $2.2K | $0 | 6 | 2025-07-01 |
| 5 | Nick B. Tressler | Chief Financial Officer | 11,712 | $2.0K | $0 | 3 | 2026-07-02 |
| 6 | Jon S Saxe | Director | 1,859 | $323 | $46.0K | 19 | 2025-09-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VTGN Board & Officers
As of SEC filings through Jul 31, 2026Directors 5
- Jon S Saxe · since May 11, 2011
- Shawn Singh · since May 11, 2011
- Ann Michelle Cunningham · since Jan 10, 2019
- Margaret M FitzPatrick · since Jul 21, 2021
- Douglas J Williamson · since Jul 29, 2026
Officers 6
- Shawn Singh · President and CEO · listed since Jun 2025
- Nick B. Tressler · Chief Financial Officer · since Dec 1, 2025
- Joshua S. Prince · Chief Operating Officer · since Oct 24, 2023
- Elissa S. Cote · Chief Corp Development Officer · since Jun 23, 2025
- Reid G. Adler · Chief Legal Officer · listed since Jun 2025
- Angel S Angelov · Chief Medical Officer · since May 18, 2026
Changes in the last 10 years (48)
| Jul 29, 2026 | Douglas J Williamson became a director |
| Jun 16, 2026 | The company announced the departure of Joanne Curley from the board in an SEC filing |
| May 18, 2026 | Angel S Angelov became Chief Medical Officer |
| Mar 17, 2026 | The company announced the departure of Mary L. Rotunno from the board in an SEC filing |
| Feb 13, 2026 | The company announced the departure of Paul R Edick from the board in an SEC filing |
| Dec 1, 2025 | Nick B. Tressler became Chief Financial Officer |
| Oct 27, 2025 | Paul R Edick became a director |
| Sep 10, 2025 | The company announced the departure of Cynthia Lynn Anderson as Chief Financial Officer in an SEC filing |
| Jun 25, 2025 | Shawn Singh listed as President and CEO (previously Chief Executive Officer) in SEC filings |
| Jun 25, 2025 | Reid G. Adler listed as Chief Legal Officer (previously Chf Corp Devel Off, Gen Couns) in SEC filings |
| Jun 23, 2025 | Elissa S. Cote became Chief Corp Development Officer |
| Mar 6, 2024 | Ann Michelle Cunningham no longer listed as Chief Commercial Officer in SEC filings |
| Jan 3, 2024 | Reid G. Adler listed as Chf Corp Devel Off, Gen Couns (previously Chief Legal Officer) in SEC filings |
| Oct 24, 2023 | Joshua S. Prince became Chief Operating Officer |
| Oct 6, 2023 | Commodore Capital LP reported in an SEC filing no longer being a 10% owner |
| Aug 21, 2023 | Cynthia Lynn Anderson became Chief Financial Officer |
| Aug 7, 2023 | Commodore Capital LP became a 10% owner |
| Jul 7, 2023 | The company announced the departure of Jerrold Duane Dotson as VP, CFO and Secretary in an SEC filing |
| Jul 14, 2022 | Venrock Healthcare Capital Partners III, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | Venrock Healthcare Capital Partners II, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | Venrock Healthcare Capital Partners EG, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | VHCP Management III, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | VHCP Management II, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | VHCP Management EG, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | VHCP Co-Investment Holdings III, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | VHCP Co-Investment Holdings II, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | Nimish P Shah reported in an SEC filing no longer being a 10% owner |
| Jul 14, 2022 | Bong Y Koh reported in an SEC filing no longer being a 10% owner |
| May 2, 2022 | Reid G. Adler became Chief Legal Officer |
| Apr 6, 2022 | Venrock Healthcare Capital Partners III, L.P. became a 10% owner |
| Apr 6, 2022 | Venrock Healthcare Capital Partners II, L.P. became a 10% owner |
| Apr 6, 2022 | Venrock Healthcare Capital Partners EG, L.P. became a 10% owner |
| Apr 6, 2022 | VHCP Management III, LLC became a 10% owner |
| Apr 6, 2022 | VHCP Management II, LLC became a 10% owner |
| Apr 6, 2022 | VHCP Management EG, LLC became a 10% owner |
| Apr 6, 2022 | VHCP Co-Investment Holdings III, LLC became a 10% owner |
| Apr 6, 2022 | VHCP Co-Investment Holdings II, LLC became a 10% owner |
| Apr 6, 2022 | Nimish P Shah became a 10% owner |
| Apr 6, 2022 | Bong Y Koh became a 10% owner |
| Jul 21, 2021 | Margaret M FitzPatrick became a director |
| Jul 6, 2021 | Mary L. Rotunno became a director |
| Jul 2, 2021 | H. Ralph Snodgrass no longer listed as a director in SEC filings |
| May 4, 2021 | Ann Michelle Cunningham first listed as Chief Commercial Officer in an SEC filing |
| Apr 23, 2021 | Joanne Curley became a director |
| Feb 1, 2021 | Mark J Ginski became Senior VP, Head of Cmc |
| Jan 10, 2019 | Ann Michelle Cunningham became a director |
| Aug 31, 2018 | Jerrold Duane Dotson listed as VP, CFO and Secretary (previously CFO and Secretary) in SEC filings |
| Sep 19, 2017 | Mark A. McPartland became VP Corporate Development |
Not reported recently (6)
- Jerry B Gin · Last reported as a director in an SEC filing dated Sep 10, 2024
- Mark Alan Smith · Last reported as Chief Medical Officer in an SEC filing dated Jul 15, 2022
- H. Ralph Snodgrass · Last reported as Pres./chief Scientific Officer in an SEC filing dated Jan 3, 2022
- Brian J. Underdown · Last reported as a director in an SEC filing dated Mar 22, 2021
- Mark J Ginski · Last reported as Senior VP, Head of Cmc in an SEC filing dated Feb 2, 2021
- Mark A. McPartland · Last reported as VP Corporate Development in an SEC filing dated Jan 4, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold VTGN
3 shown · $583.67K total exposure
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.83
TTM Revenue
$1.27M
TTM Net Income
$-69.67M
TTM Op. Cash Flow
$-66.44M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '26 | 2026-03-31 | $465.00K | $-16.27M | $-0.37 | $-16.20M |
| Q3 '26 | 2025-12-31 | $303.00K | $-18.90M | $-0.45 | $-17.63M |
| Q2 '26 | 2025-09-30 | $258.00K | $-19.40M | $-0.54 | $-13.76M |
| Q1 '26 | 2025-06-30 | $244.00K | $-15.10M | $-0.47 | $-18.85M |
| Q4 '25 | 2025-03-31 | $-15.00K | $-13.63M | $-0.44 | $-10.06M |
| Q3 '25 | 2024-12-31 | $234.00K | $-14.09M | $-0.46 | $-10.28M |
| Q2 '25 | 2024-09-30 | $183.00K | $-12.94M | $-0.42 | $-10.89M |
| Q1 '25 | 2024-06-30 | $84.00K | $-10.73M | $-0.35 | $-10.87M |
| Q4 '24 | 2024-03-31 | $197.00K | $-9.52M | $-0.25 | $-6.99M |
| Q3 '24 | 2023-12-31 | $411.00K | $-6.35M | $-0.22 | $-4.75M |
| Q2 '24 | 2023-09-30 | $278.00K | $-6.59M | $-0.66 | $-6.19M |
| Q1 '24 | 2023-06-30 | $177.00K | $-6.90M | $-0.94 | $-7.89M |
Q4 2026 • period ending 2026-03-31 • filed 2026-06-15
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.18
P/S
5.06
EV/EBITDA
—
EV/Sales
-19.18
ROE
-196.1%
ROA
-143.5%
Div Yield
0.00%
FCF Yield
-1033.21%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$6.43M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
3.75M
SI % of Float
8.71%
Days to Cover
1.00
Short Vol Ratio
44.4%
Free Float
43.08M
Float %
97.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14